Navigation Links
Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
Date:5/16/2008

59

income 57,936 455,801

Interest income, net -- (927,054)

Amortization of debt discount

and financing costs

Interest expense on convertible

notes -- (255,309)

Net Loss $(2,537,419) $(29,342,424)

Basic and Diluted Net Loss Per

Common Share $(0.15)

Basic and Diluted Weighted

Average Number of Common

Shares Outstanding 16,732,003

SENESCO TECHNOLOGIES, INC. AND SUBSIDIARY

(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, June 30,

2008 2007

(unaudited)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $4,049,233 $408,061

Short-term investments 500,000 250,000

Prepaid expenses and other current assets 57,695 104,526

Total Current Assets 4,606,928 762,587

Property and equipment, net 6,880 7,526

Intangibles, net 3,032,449 2,544,447

Deferred financing costs 729,029 --

Security deposit 7,187 7,187

TOTAL ASSETS $8,382,473 $3,321,747

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $168,525 $109,258

Accrued expenses 509,619 377,359

Deferred revenue
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
2. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
5. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
6. Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Neurobiological Technologies Reports Third Quarter Financial Results
10. InSet Technologies Appoints Jon Tremmel to its Board of Directors
11. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... ) today announced data from PERSIST-1 – a randomized ... of myelofibrosis – in a late-breaking oral session at ... of Clinical Oncology (ASCO), May 29-June 2, 2015 in ... investigational oral multikinase inhibitor with specificity for JAK2 and ...
(Date:5/29/2015)... HILL, N.C. , May 29, 2015 /PRNewswire/ ... medical affairs function into roles involving clinical development, ... As its responsibilities have grown, Medical Affairs has ... function as a global group. And while its ... find it challenging to identify strong performance metrics ...
(Date:5/29/2015)... 2015 GeneWEAVE, Inc ., ... announced that initial feasibility data supporting the use ... susceptibility testing from positive blood cultures will be ... 2015 in New Orleans, LA. The Company’s Smarticles™ ... that can quickly detect bacteria and assess antibiotic ...
(Date:5/29/2015)... Market Publishers Ltd and Shanghai ... partnership agreement for quality market research promotion on ... sell research reports worked out by Chem-Report. , ... upon the agreement: “Chem-Report is a Chinese company ... chemical markets on global and country levels. The ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3
... research team co-led by scientists from the J. Craig Venter ... of Maryland School of Medicine, today published the sequence and ... in Nature Biotechnology . Agnes P. Chan, Ph.D., JCVI, ... paper describing the 4.5X coverage of this important oilseed crop. ...
... In Vitro Toxicology Services -- MACCLESFIELD, England, August 20, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... SLN), a leading international RNAi therapeutics company, is pleased ... has announced the grant of an option to Novartis ... commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which ... conducting a Phase II clinical trial of QPI-1002 for ...
Cached Biology Technology:Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 2Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 3Cyprotex Adds In Vitro Toxicology Services 2Cyprotex Adds In Vitro Toxicology Services 3Cyprotex Adds In Vitro Toxicology Services 4Cyprotex Adds In Vitro Toxicology Services 5Cyprotex Adds In Vitro Toxicology Services 6Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... developing bipolar disorder depends in part on the combined, small ... brain, none of which is powerful enough to cause the ... the enzyme produced by one of these genes could lead ... was conducted by scientists at the National Institutes of Health's ...
... their effects on fat development, researchers have discovered that ... mice without some of the side effects attributed to ... harmine, was first isolated more than 150 years ago ... around the world, the team reports in the May ...
... it express who we are, but is it really possible to ... to that question seems to be related to fashion and glamour, ... Mexico and the Buck Institute in the USA, were able to ... In biology, the capacity to establish the function of a molecule, ...
Cached Biology News:Genetic roots of bipolar disorder revealed by first genome-wide study of illness 2Genetic roots of bipolar disorder revealed by first genome-wide study of illness 3Fat screen delivers plant-derived chemical with antidiabetic effects 2
... Helios gene gun system, 220-240 V, is ... into cells. This handheld device employs an ... and other biomaterial-coated gold microcarriers from the ... directly into target cells. This system has ...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
... a DNA sequencing service. We can sequence ... products, BACs, etc. Our DNA sequencing service ... plasmids or purified PCR products. We use ... automated reaction setup and dye terminator removal. ...
... The BD FACSAria cell sorter sets a ... Based on a revolutionary new design ... high-speed sorting and multicolor analysis. The BD ... that incorporates a fixed-alignment cuvette flow cell. ...
Biology Products: